CBL0137

Catalog No.S0507 Synonyms: Curaxin-137, CBL-C137, CBLC137

For research use only.

CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.

CBL0137 Chemical Structure

CAS No. 1197996-80-7

Selleck's CBL0137 has been cited by 4 Publications

Purity & Quality Control

Choose Selective NF-κB Inhibitors

Other NF-κB Products

Biological Activity

Description CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively.
Targets
FACT [1] p53 [1]
(Cell-free assay)
NF-κB [1]
(Cell-free assay)
0.37 μM(EC50) 0.47 μM(EC50)

Protocol (from reference)

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 336.43
Formula

C21H24N2O2

CAS No. 1197996-80-7
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles CC(C)NCCN1C2=C(C=C(C=C2)C(=O)C)C3=C1C=CC(=C3)C(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04870944 Not yet recruiting Drug: FACT Complex-targeting Curaxin CBL0137 Diffuse Midline Glioma H3 K27M-Mutant|Metastatic Malignant Neoplasm in the Central Nervous System|Recurrent Diffuse Intrinsic Pontine Glioma|Recurrent Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Osteosarcoma|Recurrent Primary Malignant Central Nervous System Neoplasm|Refractory Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Osteosarcoma|Refractory Primary Malignant Central Nervous System Neoplasm Children''s Oncology Group|Incuron LLC|National Cancer Institute (NCI) February 10 2022 Phase 1|Phase 2

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy CBL0137 | CBL0137 supplier | purchase CBL0137 | CBL0137 cost | CBL0137 manufacturer | order CBL0137 | CBL0137 distributor